{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:53:19Z","timestamp":1793566399330,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/hjh.0b013e3281c49d93","type":"journal-article","created":{"date-parts":[[2007,7,9]],"date-time":"2007-07-09T08:05:22Z","timestamp":1183968322000},"page":"1711-1718","source":"Crossref","is-referenced-by-count":14,"title":["Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome"],"prefix":"10.1097","volume":"25","author":[{"given":"Luis M","family":"Ruilope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget-Anne","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"de Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Danchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith AA","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A","family":"Poole-Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus","family":"Lubsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20210227","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0272-6386(03)00826-6","article-title":"Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the Institute of Diabetes and Digestive and Kidney Disease (NIDDK)","volume":"42","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R2-27-20210227","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0002-9149(03)00822-1","article-title":"Mild renal insufficiency and risk of congestive heart failure in men and women > or = 70 years of age","volume":"92","author":"Chae","year":"2003","journal-title":"Am J Cardiol"},{"key":"R3-27-20210227","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-27-20210227","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1097\/01.ASN.0000095642.25603.7A","article-title":"Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study","volume":"14","author":"Ix","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 5","key":"R5-27-20210227","doi-asserted-by":"crossref","first-page":"I80","DOI":"10.1161\/01.HYP.13.5_Suppl.I80","article-title":"Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program","volume":"13","author":"Shulman","year":"1989","journal-title":"Hypertension"},{"key":"R6-27-20210227","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V122218","article-title":"Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) study","volume":"12","author":"Ruilope","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R7-27-20210227","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"R8-27-20210227","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","article-title":"The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann Intern Med"},{"key":"R9-27-20210227","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"R10-27-20210227","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1681\/ASN.2004110969","article-title":"Calcium channel blockers and renal protection, insights from the latest clinical trials","volume":"16","author":"Segura","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R11-27-20210227","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1001\/archinte.164.22.2459","article-title":"Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial","volume":"164","author":"de Leeuw","year":"2004","journal-title":"Arch Intern Med"},{"key":"R12-27-20210227","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"key":"R13-27-20210227","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/00004872-200018110-00003","article-title":"Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure","volume":"18","author":"Ruilope","year":"2000","journal-title":"J Hypertens"},{"key":"R14-27-20210227","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"R15-27-20210227","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/01.CIR.92.5.1326","article-title":"Nifedipine. Dose-related increase in mortality in patients with coronary heart disease","volume":"92","author":"Furberg","year":"1995","journal-title":"Circulation"},{"key":"R16-27-20210227","first-page":"1475","article-title":"Corrections to the nifedipine meta-analysis","volume":"93","author":"Furberg","year":"1996","journal-title":"Circulation"},{"key":"R17-27-20210227","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jama.1995.03530080036038","article-title":"The risk of myocardial infarction associated with antihypertensive drug therapies","volume":"274","author":"Psaty","year":"1995","journal-title":"JAMA"},{"key":"R18-27-20210227","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1161\/01.CIR.91.12.2855","article-title":"The calcium channel blocker scare. Lessons for the future","volume":"91","author":"Lenfant","year":"1995","journal-title":"Circulation"},{"key":"R19-27-20210227","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/01.CIR.92.5.1068","article-title":"Nifedipine and mortality. Grave defects in the dossier","volume":"92","author":"Opie","year":"1995","journal-title":"Circulation"},{"issue":"Suppl I","key":"R20-27-20210227","first-page":"I20","article-title":"Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS","volume":"19","author":"Lubsen","year":"1998","journal-title":"Eur Heart J"},{"key":"R21-27-20210227","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"R24-27-20210227","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R25-27-20210227","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1002\/(SICI)1097-0258(19971230)16:24<2855::AID-SIM749>3.0.CO;2-Y","article-title":"Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics","volume":"16","author":"Frison","year":"1997","journal-title":"Stat Med"},{"key":"R26-27-20210227","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.hjh.0000160223.94220.29","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial","volume":"23","author":"Lubsen","year":"2005","journal-title":"J Hypertens"},{"key":"R27-27-20210227","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril. The HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"R28-27-20210227","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-140-3-200402030-00007","article-title":"The metabolic syndrome and chronic kidney disease in US adults","volume":"140","author":"Chen","year":"2004","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"R29-27-20210227","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1097\/01.ASN.0000034496.63958.F8","article-title":"The kidney as a sensor of cardiovascular risk in essential hypertension","volume":"13","author":"Ruilope","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R30-27-20210227","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0735-1097(01)01627-8","article-title":"Renal function, the cinderella of cardiovascular risk profile","volume":"38","author":"Ruilope","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R31-27-20210227","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0195-668X(02)00526-2","article-title":"Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial","volume":"24","author":"Hillege","year":"2003","journal-title":"Eur Heart J"},{"key":"R32-27-20210227","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach National Kidney Foundation. Hypertension and Diabetes Executive Committee Working Groups","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R33-27-20210227","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000072054","article-title":"Role of actions of calcium antagonists on efferent arterioles \u2013 with special references to glomerular hypertension","volume":"23","author":"Hayashi","year":"2003","journal-title":"Am J Nephrol"},{"key":"R34-27-20210227","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1523-1755.2004.00484.x","article-title":"The impact of serum uric acid on cardiovascular outcome in the LIFE study","volume":"65","author":"Hoieggen","year":"2004","journal-title":"Kidney Int"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-200708000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T21:32:10Z","timestamp":1629322330000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-200708000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3281c49d93","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}